Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 267

1.

E2F1-Mediated Induction of NFYB Attenuates Apoptosis via Joint Regulation of a Pro-Survival Transcriptional Program.

Jiang X, Nevins JR, Shats I, Chi JT.

PLoS One. 2015 Jun 3;10(6):e0127951. doi: 10.1371/journal.pone.0127951. eCollection 2015.

2.

ASSOCIATIONS BETWEEN ULTRASOUND AND CLINICAL FINDINGS IN 87 CATS WITH URETHRAL OBSTRUCTION.

Nevins JR, Mai W, Thomas E.

Vet Radiol Ultrasound. 2015 Jul-Aug;56(4):439-47. doi: 10.1111/vru.12259. Epub 2015 Apr 8.

PMID:
25850697
3.

Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.

Rempel RE, Jiang X, Fullerton P, Tan TZ, Ye J, Lau JA, Mori S, Chi JT, Nevins JR, Friedman DR.

Mol Cancer Ther. 2014 Dec;13(12):3219-29. doi: 10.1158/1535-7163.MCT-13-0044. Epub 2014 Oct 27.

4.

Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control.

Dong P, Maddali MV, Srimani JK, Thélot F, Nevins JR, Mathey-Prevot B, You L.

Nat Commun. 2014 Sep 1;5:4750. doi: 10.1038/ncomms5750.

5.

FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.

Shats I, Gatza ML, Liu B, Angus SP, You L, Nevins JR.

Cancer Res. 2013 Oct 1;73(19):6056-67. doi: 10.1158/0008-5472.CAN-13-0453. Epub 2013 Aug 21.

6.

Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression.

Liu B, Shats I, Angus SP, Gatza ML, Nevins JR.

J Biol Chem. 2013 Aug 23;288(34):24581-9. doi: 10.1074/jbc.M113.467506. Epub 2013 Jul 13.

7.

E2F6 associates with BRG1 in transcriptional regulation.

Leung JY, Nevins JR.

PLoS One. 2012;7(10):e47967. doi: 10.1371/journal.pone.0047967. Epub 2012 Oct 17.

8.

A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest.

Angus SP, Nevins JR.

Oncogene. 2012 Nov 1;31(44):4709-17. doi: 10.1038/onc.2011.622. Epub 2012 Jan 16.

9.

Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2012 Feb 1;307(5):453. doi: 10.1001/jama.2012.2. Epub 2012 Jan 6. No abstract available.

PMID:
22228686
10.

SIGNATURE: a workbench for gene expression signature analysis.

Chang JT, Gatza ML, Lucas JE, Barry WT, Vaughn P, Nevins JR.

BMC Bioinformatics. 2011 Nov 14;12:443. doi: 10.1186/1471-2105-12-443.

11.

Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.

Leung JY, Andrechek ER, Cardiff RD, Nevins JR.

Oncogene. 2012 May 17;31(20):2545-54. doi: 10.1038/onc.2011.433. Epub 2011 Sep 26.

12.

Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17569. doi: 10.1073/pnas.1115170108. Epub 2011 Oct 3. No abstract available.

13.

Network calisthenics: control of E2F dynamics in cell cycle entry.

Wong JV, Dong P, Nevins JR, Mathey-Prevot B, You L.

Cell Cycle. 2011 Sep 15;10(18):3086-94. Epub 2011 Sep 15. Review.

14.

Peripheral blood signatures of lead exposure.

LaBreche HG, Meadows SK, Nevins JR, Chute JP.

PLoS One. 2011;6(8):e23043. doi: 10.1371/journal.pone.0023043. Epub 2011 Aug 1.

15.

Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors.

LaBreche HG, Nevins JR, Huang E.

BMC Med Genomics. 2011 Jul 22;4:61. doi: 10.1186/1755-8794-4-61.

16.

A methodology for utilization of predictive genomic signatures in FFPE samples.

Freedman JA, Augustine CK, Selim AM, Holshausen KC, Wei Z, Tsamis KA, Hsu DS, Dressman HK, Barry WT, Tyler DS, Nevins JR.

BMC Med Genomics. 2011 Jul 11;4:58. doi: 10.1186/1755-8794-4-58.

17.

Use of gene expression and pathway signatures to characterize the complexity of human melanoma.

Freedman JA, Tyler DS, Nevins JR, Augustine CK.

Am J Pathol. 2011 Jun;178(6):2513-22. doi: 10.1016/j.ajpath.2011.02.037.

18.

Using noisy gene expression mediated by engineered adenovirus to probe signaling dynamics in mammalian cells.

Wong JV, Yao G, Nevins JR, You L.

Methods Enzymol. 2011;497:221-37. doi: 10.1016/B978-0-12-385075-1.00010-X.

PMID:
21601089
19.

Pathway-based classification of lung cancer: a strategy to guide therapeutic selection.

Nevins JR.

Proc Am Thorac Soc. 2011 May;8(2):180-2. doi: 10.1513/pats.201006-040MS.

20.

Origin of bistability underlying mammalian cell cycle entry.

Yao G, Tan C, West M, Nevins JR, You L.

Mol Syst Biol. 2011 Apr 26;7:485. doi: 10.1038/msb.2011.19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk